Cutaneous Squamous Cell Carcinoma: Managing Advanced Disease in the Era of Immunotherapy (Virtual GR)
Credit(s): 1.00 (60 min)
3/5/2021 - 12:15 - 1:15 PM ET
CME / AMA PRA Category 1 Credit™
Most cases of cutaneous squamous cell carcinoma (cSCC), a common cancer, are recognized early and treated successfully with surgery. A small percentage of patients develop advanced or metastatic disease, in which case data to guide treatments are sparse and management depends on a patient’s level of disability and comorbidities. Because patients with de novo or post-surgical advanced or metastatic cSCC are rare, oncologists aren’t always acquainted with pathophysiology, recommendations for diagnostic evaluations, disease staging, management strategies, or agents in clinical trials. Research is contributing to a greater understanding of tumor molecular markers (e.g. overexpression of EGFR) and the role of the programmed death-1 (PD-1) pathway, and has led to the use of targeted agents and the first FDA-approved agent (a PD-1 inhibitor) to treat advanced and metastatic cSCC.
This activity will help clinicians recognize and thoroughly evaluate and stage patients with cSCC who are at high risk of advanced or metastatic disease. Participants should then be able to use this information, in conjunction with expert recommendations and the multidisciplinary team, to develop treatment plans. Up-to-date knowledge of cSCC pathophysiology, including the role of mutations, EGFR overexpression, and the immune system, will give clinicians an understanding of where newly approved and in-development agents fit in treatment strategies.
Welcome and Introductions
Staging of cSCC
Current Understanding of the Pathophysiology of Advanced/Metastatic cSCC
Evolving Paradigm for Managing Advanced/Metastatic cSCC
Q&A Session and Activity Roundup
This activity is intended for oncologists, oncology nurses, pharmacists, and other healthcare professionals involved in the treatment and care of patients with cSCC.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
Outline the diagnostic evaluation of patients with cSCC
Describe commonly used systems for staging cSCC
Review the current understanding of the pathophysiology of advanced and metastatic cSCC
Review current recommendations for developing individualized management plans for advanced and metastatic cSCC, including the need for a multidisciplinary team
Describe the efficacy and safety of immune-targeted agents newly approved for the management of cSCC
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email email@example.com.
Emily Stamell Ruiz, MD, MPH
Director, Dana‐Farber/Brigham and Women's High‐Risk Skin Cancer Clinic
Dana‐Farber/Brigham and Women's Cancer Center
Instructor in Dermatology
Harvard Medical School
Emily Stamell Ruiz, MD, MPH is Director of the Dana-Farber/Brigham and Women’s High-Risk Skin Cancer Clinic, an Associate Physician at the Mohs and Dermatologic Surgery Center at Dana-Farber/Brigham and Women’s Cancer Center, and an Instructor in Dermatology at Harvard Medical School. Dr. Ruiz received her undergraduate degree from Duke University, her medical degree from New York University School of Medicine, and her Master of Public Health degree from Harvard School of Public Health.
Dr. Ruiz completed an internship in internal medicine at New York University School of Medicine, a dermatology residency at Albert Einstein College of Medicine, and a fellowship in micrographic surgery and dermatologic oncology at Brigham and Women’s Hospital. Dr. Ruiz’s research focuses on the burden of skin cancer through health services research and nonmelanoma skin cancer outcomes studies.
Ann Silk, MD, MS
Dana-Farber Cancer Institute
Ann W. Silk, MD, MS is a medical oncologist at Dana‐Farber Cancer Institute, where she specializes in the care of patients with advanced skin cancers, including squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, and melanoma. She conducts clinical trials using immuno-therapeutics, such as immune checkpoint inhibitors, cytokine therapy, and oncolytic viral therapy.
Dr. Silk received her medical doctorate and master’s degree in clinical research at the University of Pittsburgh in 2008. She completed a clinical fellowship in hematology and oncology at the University of Michigan in 2014. She joined the faculty at Dana-Farber Cancer Institute in 2019.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 80% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
Jointly provided by USF Health and Rockpointe
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.